Oryzon Genomics FY26 H1 net loss narrows to EUR 1.37 million; operating loss widens to EUR 3.13 million

Reuters2026/07/27 18:13

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oryzon Genomics posted a net loss of EUR 1.37 million, narrowing from EUR 1.54 million a year earlier.
Operating loss widened to EUR 3.13 million from EUR 2.93 million, while the financial result swung to a loss of EUR 77,000 from a EUR 107,000 gain.
Capitalized development work rose to EUR 8.69 million from EUR 4.22 million, while other operating income climbed to EUR 644,000 from EUR 26,000.
Cash and cash equivalents fell to EUR 14.68 million at June 30 from EUR 28.35 million at end-2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oryzon Genomics SA published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oryzon Genomics FY26 H1 net loss narrows to EUR 1.37 million; operating loss widens to EUR 3.13 million

You may also like

Crypto prices